Literature DB >> 15337228

Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery.

Philip Raake1, Georges von Degenfeld, Rabea Hinkel, Robert Vachenauer, Torleif Sandner, Sabrina Beller, Martin Andrees, Christian Kupatt, Gerhard Schuler, Peter Boekstegers.   

Abstract

OBJECTIVES: We sought to study adenoviral gene delivery using percutaneous selective pressure-regulated retroinfusion and to compare it directly with surgical and percutaneous intramyocardial delivery (PIMD) for the first time.
BACKGROUND: Intramyocardial delivery (IMD) has been recommended to be the preferred gene delivery strategy so far. However, surgical and percutaneous intramyocardial injection lead to incomplete retention of the injected viral vectors and to limited spatial myocardial distribution. Percutaneous selective pressure-regulated retroinfusion of the coronary veins was developed recently to provide an effective and more homogenous regional myocardial gene transfer.
METHODS: In 15 pigs, adenoviral vectors (Ad2-CMV beta-galactosidase [beta-gal] 5 x 10(9) pfu) were applied via surgical IMD (n = 5), PIMD (n = 5), and selective pressure-regulated retroinfusion (n = 5). Seven days after gene transfer, myocardial beta-gal expression was measured by ELISA.
RESULTS: Selective retroinfusion into the anterior cardiac vein substantially increased reporter gene expression (1,039 +/- 79 pg beta-gal/mg protein) in the targeted left anterior descending coronary artery territory when compared with surgical (448 +/- 127, p < 0.05) and PIMD (842 +/- 145, p < 0.05). Both IMD approaches showed an inhomogenous beta-gal expression, particularly along the injection sites, while retroinfusion resulted in a more homogenous transmural gene expression.
CONCLUSIONS: Percutaneous selective pressure-regulated retroinfusion compares favorably with surgical and percutaneous intramyocardial injection techniques by providing a more homogenous and even more efficient adenoviral gene delivery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337228     DOI: 10.1016/j.jacc.2004.05.074

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

Review 1.  Delivery of gene and cellular therapies for heart disease.

Authors:  Justin A Mariani; David M Kaye
Journal:  J Cardiovasc Transl Res       Date:  2010-05-11       Impact factor: 4.132

Review 2.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

3.  State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association.

Authors:  Michael Simons; Kari Alitalo; Brian H Annex; Hellmut G Augustin; Craig Beam; Bradford C Berk; Tatiana Byzova; Peter Carmeliet; William Chilian; John P Cooke; George E Davis; Anne Eichmann; M Luisa Iruela-Arispe; Eli Keshet; Albert J Sinusas; Christiana Ruhrberg; Y Joseph Woo; Stefanie Dimmeler
Journal:  Circ Res       Date:  2015-04-30       Impact factor: 17.367

Review 4.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 5.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 6.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

Review 7.  Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Authors:  Shaina R Eckhouse; Jeffrey A Jones; Francis G Spinale
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

8.  Engineered Biomaterials to Enhance Stem Cell-Based Cardiac Tissue Engineering and Therapy.

Authors:  Anwarul Hasan; Renae Waters; Boustany Roula; Rahbani Dana; Seif Yara; Toubia Alexandre; Arghya Paul
Journal:  Macromol Biosci       Date:  2016-03-08       Impact factor: 4.979

Review 9.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 10.  Intracoronary delivery of bone-marrow-derived stem cells.

Authors:  Quang T Bui; Zachary M Gertz; Robert L Wilensky
Journal:  Stem Cell Res Ther       Date:  2010-09-23       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.